Dividends & Buybacks ·
United Therapeutics authorizes $2 billion share repurchase program valid through October 2027
UTHRUNITED THERAPEUTICS Corp
The Board of Directors approved a new share repurchase program authorizing the purchase of up to $2.0 billion of common stock, effective for one year ending October 21, 2027. The company may execute buybacks via accelerated share repurchases, open market transactions, or privately negotiated deals. An existing ASR transaction from September 2026 will not reduce the new authorization amount. United Therapeutics develops therapies and technologies to treat rare diseases and expand the supply of transplantable organs.